Note: This is the approval of Zepatier in CANADA for genotype 1, 3 or 4. Included are videos and a PDF of the medication of guide.
ZEPATIER Achieves High Cure Rates* (SVR12) of 95-98% in Broad Range of Patients with Chronic Hepatitis C Infection, Including Those with Compensated Cirrhosis, Renal Impairment of Any Degree and HIV-1/HCV Co-infection
KIRKLAND, QC, Feb. 3, 2016 /CNW Telbec/ – Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today that ZEPATIER (elbasvir/grazoprevir) is now available in Canada. It is indicated for the treatment of chronic hepatitis C (CHC) genotypes 1, 3 or 4 infections in adults; see the About ZEPATIER section below for full indication details.1
“We value this accelerated approval of ZEPATIER in Canada which allows us to offer an effective, simple and well tolerated treatment not only for Canadians with the hepatitis C virus with genotype 1 infection, but also for genotype 3 and 4 infected patients for whom options were limited until now,” says Chirfi Guindo, President and Managing Director, Merck Canada Inc. “With this new product, we now have the opportunity to help a broad range of patients overcome hepatitis C using a simple regimen of 1 pill daily, with most patients cured with an 8 to 12-week therapy.”